Page 145 - COVID-19 COUNTRY REPORT: Moving Beyond Pandemic EDITION 2022

National Institutes of Health

15. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, et al.
Molnupiravir for Oral Treatment of COVID-19 in Nonhospitalized Patients. N Engl J Med [Internet].
2022 Feb 10;386(6):509–20. Available from: http://www.nejm.org/doi/10.1056/NEJMoa2116044
16. Kaos JR J. Khairy: Malaysia, Merck sign agreement for COVID-19 drug Molnupiravir. The Star Online
[Internet]. 2021 Oct 7; Available from: https://www.thestar.com.my/news/nation/2021/10/07/
khairy-malaysia-merck-sign-agreement-for-COVID-19-drug-molnupiravir#:~:text=PUTRAJAYA%
3A Malaysia has signed an,to treat COVID-19 patients
17. CodeBlue. NPRA Approves COVID-19 Medicine To Protect Immunocompromised Before Exposure
[Internet]. Code Blue. 2022 [cited 2023 15 February]. Available from: https://codeblue.galencentre.
org/2022/05/13/npra-approves-COVID-19-medicine-to-protect-immunocompromised-before-
exposure/
18. Gordon CJ, Tchesnokov EP, Woolner E, Perry JK, Feng JY, Porter DP, et al. Remdesivir is a direct-
acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory
syndrome coronavirus 2 with high potency. J Biol Chem [Internet]. 2020 May;295(20):6785–97.
Available from: https://linkinghub.elsevier.com/retrieve/pii/S0021925817481865
19. Boglione L, Dodaro V, Meli G, Rostagno R, Poletti F, Moglia R, et al. Remdesivir treatment in
hospitalised patients affected by COVID‐19 pneumonia: A case‐control study. J Med Virol
[Internet]. 2022 Aug 19;94(8):3653–60. Available from: https://onlinelibrary.wiley.com/doi/10.1002/
jmv.27768
20. Hisham AN. Kenyataan Akhbar KPK 7 Julai 2022 – Keputusan Mesyuarat Pihak Berkuasa
Kawalan Dadah Kali Ke–374 Berkenaan Pendaftaran Produk Bagi Rawatan COVID-19 [Internet].
From the Desk of the Director-General of Health Malaysia. 2022 [cited 2023 Feb 12]. Available
from: https://kpkesihatan.com/2022/07/07/kenyataan-akhbar-kpk-7-julai-2022-keputusan-
mesyuarat-pihak-berkuasa-kawalan-dadah-kali-ke-374-berkenaan-pendaftaran-produk-bagi-
rawatan-COVID-19/ Chapter 6
21. Hisham AN. Joint Press Release MOH-WHO 6 April 2020 – Malaysia starts global “Solidarity
Trial” – a research effort to test possible treatments for COVID-19 [Internet]. From the Desk of the
Director-General of Health Malaysia. 2022. Available from: https://kpkesihatan.com/2020/04/06/
joint-press-release-moh-who-6-april-2020-malaysia-starts-global-solidarity-trial-a-research-
effort-to-test-possible-treatments-for-COVID-19
22. Zhang S, Li L, Shen A, Chen Y, Qi Z. Rational Use of Tocilizumab in the Treatment of Novel
Coronavirus Pneumonia. Clin Drug Investig [Internet]. 2020;40(6):511–8. Available from: https://
doi.org/10.1007/s40261-020-00917-3
23. Mushtaq MZ, Mahmood SBZ, Almas A, Ather Wasti S, Ahsan Ali S. Tocilizumab in critically ill
COVID-19 patients: An observational study. Int Immunopharmacol. 2022 Jan;102:108384.
24. Moy F-M, Hairi N, Lim E, Bulgiba A. Long COVID and its associated factors among COVID survivors
in the community from a middle-income country—An online cross-sectional study. PLoS One.
2022 Aug;17:e0273364–e0273364.
25. WHO. Home/Newsroom/Fact Sheets/Post COVID-19 condition (Long COVID): Post COVID-19
condition (Long COVID) [Internet]. World Health Organization. 2022. Available from: https://
www.who.int/europe/news-room/fact-sheets/item/post-COVID-19-condition
26. WHO. WHO Coronavirus WHO Coronavirus [Internet]. Who website. 2022. Available from: https://
covid19.who.int/
27. Beusekom M Van. Global data reveal half may have long COVID 4 months on. CIDRAP News
[Internet]. 2022; Available from: https://www.cidrap.umn.edu/global-data-reveal-half-may-have-
long-covid-4-months
28. CDC. Long COVID [Internet]. Centres for Disease Control and Prevention. 2022. Available from:
https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html
29. Greenhalgh T, Knight M, A’Court C, Buxton M, Husain L. Management of post-acute COVID-19 in
primary care. BMJ [Internet]. 2020 Aug;370:m3026–m3026. Available from: https://covid19.who.
int/
30. Raveendran A V, Jayadevan R, Sashidharan S. Long COVID: An overview. Diabetes Metab Syndr
Clin Res Rev [Internet]. 2021;15(3):869–75. Available from: https://www.sciencedirect.com/
science/article/pii/S1871402121001193
31. Michelen M, Manoharan L, Elkheir N, Cheng V, Dagens A, Hastie C, et al. Characterising long
COVID: a living systematic review. BMJ Glob Heal. 2021 Sep;6(9).
32. Aiyegbusi OL, Hughes SE, Turner G, Rivera SC, McMullan C, Chandan JS, et al. Symptoms,

Chapter 6 -Evolution of COVID-19 Patient Management 135